March 8, 2006

Cortex Pharmaceuticals' lead ampakine drug CX717 has shown positive results in the treatment of adults with ADHD in a Phase IIa trial. The company undertook this clinical trial to assess both the dose of drug required and the effectiveness of CX717 in an adult ADHD population. The primary outcome measure was the ADHD Rating Scale (ADHD-RS), which evaluates both the inattentiveness and hyperactivity symptoms.

The overall ADHD-RS score showed a positive trend in the 800mg twice-daily dose group, with a statistically significant effect on the hyperactivity subscale compared to placebo. The 200mg twice-daily dose did not show a significant effect.

CX717 was well-tolerated, and there were no serious adverse events or other significant safety concerns with either dose. Furthermore, no increases in blood pressure or heart rate were observed with either dose of CX717.